Physician profile
Vanessa C Pinter
NPI 1891140042
$5,250.92
in general payments reported to CMS, 2019-2025
44 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $1,003 · 2021: $1,290 · 2022: $693 · 2023: $799 · 2024: $566 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.43 | 2020-2025 | |
| Novo Nordisk INC | $1,053.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $404.37 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $348.67 | 2020-2025 | |
| Amgen INC. | $341.27 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $305.49 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $198.68 | 2020-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $177.21 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.71 | 2020-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.14 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $96.81 | 2019-2025 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $78.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $63.30 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $61.34 | 2020-2021 | |
| Alkermes, INC. | $61.12 | 2025 | Aristada, Vivitrol, Lybalvi |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Pinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.